🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 14 Sep 2026 · ClinicalTrials.gov

Clinical Trials in the UK

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

111
Recruiting now
160
Studies tracked
126
Cities with sites
Recruiting Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC · started 2024-06-24
Bristol · Truro · London · Edinburgh · Leeds
NCT06393374 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Amgen · started 2023-11-16
Birmingham · Inverness · London · Northwood · Nottingham
NCT05920356 on ClinicalTrials.gov ↗
Active Phase 2
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals · started 2023-08-16
Glasgow · London
NCT05885555 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines · started 2021-09-13
Edinburgh · Leeds · Newcastle upon Tyne · Newmarket · Norwich
NCT05006716 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ovarian Cancer, Non-small Cell Lung Cancer
Tubulis GmbH · started 2024-06-12
London
NCT06303505 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-06-30
London · Dundee · Huddersfield · Colchester · Orpington
NCT06966700 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative Colitis
AbbVie · started 2025-07-28
Cambridge · Sheffield · Liverpool
NCT07071519 on ClinicalTrials.gov ↗
Recruiting
The PERSEVERE Study
Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical · started 2024-12-16
London
NCT06588634 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
Merck Sharp & Dohme LLC · started 2026-04-23
Cambridge · London
NCT07419295 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines · started 2026-01-22
Birmingham · Bournemouth · Leeds · London · Norwich
NCT07277231 on ClinicalTrials.gov ↗
By invitation Phase 3
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Biogen · started 2022-06-10
London · Doncaster · Cannock
NCT05352919 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC · started 2024-08-16
Birmingham · Newcastle upon Tyne · London · Sutton · Cardiff
NCT06395103 on ClinicalTrials.gov ↗
Recruiting Phase 1
Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers
Fibrostenotic Crohn's Disease
Agomab Spain S.L.U. · started 2026-09-09
Nottingham
NCT07672574 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
Endometriosis
Gesynta Pharma AB · started 2025-10-15
Bradford · Bristol · Corby · Coventry · London
NCT07260669 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
Primary Membranous Nephropathy
AstraZeneca · started 2026-03-28
London · Manchester
NCT07571746 on ClinicalTrials.gov ↗
Recruiting
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
Boston Scientific Corporation · started 2024-01-29
London
NCT06553625 on ClinicalTrials.gov ↗
Active Phase 2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Chronic Hepatitis B Infection
Aligos Therapeutics · started 2025-07-15
Glasgow · Leicester · London
NCT06963710 on ClinicalTrials.gov ↗
Active Phase 2
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Gilead Sciences · started 2023-12-05
Bury · Cambridge · London · Norwich · Southampton
NCT06029972 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC · started 2026-05-03
Plymouth · Manchester
NCT07519772 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Asthma
AstraZeneca · started 2023-08-24
Birmingham · Bradford · Bristol · Glasgow · Leicester
NCT06023589 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Psoriatic Arthritis
Bristol-Myers Squibb · started 2021-07-15
London · Bradford · Hull · Liverpool · Manchester
NCT04908189 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2024-04-03
Cambridge · Northwood · London · Oxford · Newcastle upon Tyne
NCT06312137 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS · started 2025-06-05
London
NCT06797999 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Castration-Resistant Prostatic Cancer, Metastasis
Merck Sharp & Dohme LLC · started 2025-07-03
Cambridge · London
NCT06863272 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines · started 2022-03-10
Glasgow · Greater Manchester · Huddersfield · Inverness · Leeds
NCT05100862 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
AbbVie · started 2023-12-11
Sheffield · London · Birmingham
NCT05995353 on ClinicalTrials.gov ↗
Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
Hoffmann-La Roche · started 2025-07-15
Birmingham · Guildford · Leeds · Middlesbrough · Norfolk
NCT07284121 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
Regeneron Pharmaceuticals · started 2023-12-12
Truro · Plymouth · Bournemouth · Glasgow · Norwich
NCT06091254 on ClinicalTrials.gov ↗
Active
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
Tachycardia, Ventricular, Arrhythmia, Ventricular
Boston Scientific Corporation · started 2021-07-20
Leeds · Liverpool · Manchester · Southampton
NCT04798768 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-Stage Small Cell Lung Cancer
Bristol-Myers Squibb · started 2025-02-25
Central Middlesbrough · Aberdeen · Manchester · Metropolitan Borough of Wirral
NCT06646276 on ClinicalTrials.gov ↗
Recruiting
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Pain
Boston Scientific Corporation · started 2012-11-19
Basildon · Bristol · Leeds · London · Middlesbrough
NCT01719055 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Atopic Dermatitis
UCB Biopharma SRL · started 2025-12-29
London · Salford · Sheffield
NCT07277660 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca · started 2024-04-12
Airdrie · Barnet · Cambridge · Clydebank · Exeter
NCT06307652 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals · started 2022-12-30
Birmingham · Leeds · London
NCT05648968 on ClinicalTrials.gov ↗
Active Phase 3
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Hypertension
Mineralys Therapeutics Inc. · started 2023-07-14
Newquay · Fowey · Glasgow · Chippenham · Cambridge
NCT05968430 on ClinicalTrials.gov ↗
Active
CHAMPION-AF Clinical Trial
Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation · started 2020-10-15
Brighton · Leicester · Oxford
NCT04394546 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Hoffmann-La Roche · started 2020-01-29
London · Northwood · Oxford · Plymouth
NCT04191499 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non Small Cell Lung Carcinoma
AbbVie · started 2025-03-06
Leicester · Cardiff
NCT06772623 on ClinicalTrials.gov ↗
Active Phase 2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Non-small Cell Lung Cancer NSCLC
AstraZeneca · started 2018-12-21
Dundee · Hull
NCT03775486 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca · started 2024-08-22
Cambridge · Glasgow · Manchester
NCT06535607 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma
Genmab · started 2023-02-08
Birmingham · London · Norwich · Edinburgh
NCT05578976 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Hemophilia B
Regeneron Pharmaceuticals · started 2024-09-11
Glasgow · Birmingham · Cambridge · London
NCT06379789 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Regeneron Pharmaceuticals · started 2018-05-21
Oxford · Sutton · London · Manchester
NCT03564340 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen · started 2022-09-13
London · Manchester · Birmingham · Leeds
NCT05531565 on ClinicalTrials.gov ↗
Recruiting Phase 3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Arthritis, Psoriatic
MoonLake Immunotherapeutics AG · started 2024-10-15
Westcliff-on-Sea · Barnet · Leeds · Wolverhampton
NCT06641089 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Primary Membranous Nephropathy
BeOne Medicines · started 2023-04-17
Aberdeen · Derby
NCT05707377 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche · started 2021-10-22
Cambridge · Cardiff · London · Manchester · Sutton
NCT04929223 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines · started 2025-09-04
Brighton · Canterbury · Norwich · Oxford · Roundhay
NCT06973187 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Hoffmann-La Roche · started 2019-11-11
Birmingham · Manchester
NCT04140500 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
AstraZeneca · started 2021-10-18
Cambridge · Cardiff · London
NCT05123482 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Merck Sharp & Dohme LLC · started 2026-01-19
Edinburgh · Withington
NCT07216703 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Endometrial Cancer
Merck Sharp & Dohme LLC · started 2025-05-22
East Sussex · Cambridge · Glasgow · London · Edinburgh
NCT06952504 on ClinicalTrials.gov ↗
Active Phase 2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Gilead Sciences · started 2022-05-30
Birmingham · London
NCT05186974 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals · started 2025-05-30
Glasgow · London
NCT06784752 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Pulmonary Arterial Hypertension
35Pharma Inc · started 2026-08-19
London
NCT07143448 on ClinicalTrials.gov ↗
Recruiting Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
AstraZeneca · started 2025-11-10
London
NCT07228364 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC · started 2025-04-15
Brighton · Fulham · Sutton · London · Manchester
NCT06843447 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC · started 2026-04-09
Edinburgh · Leicester · Withington · Birmingham
NCT07489495 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Stereotypical Prolonged Seizures
UCB Biopharma SRL · started 2021-12-07
Birmingham · Cardiff · Glasgow · London · Oxford
NCT05077904 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Ovarian Neoplasms, Ovarian Cancer
Merck Sharp & Dohme LLC · started 2026-02-16
Cambridge · Leicester · London · Manchester
NCT07318558 on ClinicalTrials.gov ↗
Active Phase 3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Prostatic Neoplasms
Novartis Pharmaceuticals · started 2021-06-15
Guildford · Sutton · Coventry · London · Middlesbrough
NCT04689828 on ClinicalTrials.gov ↗
Active Phase 2
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche · started 2020-11-27
Harlow · London · Nottingham · Peterborough
NCT04576455 on ClinicalTrials.gov ↗
Active Phase 3
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Obesity
Novo Nordisk A/S · started 2026-04-21
Macclesfield · Rotherham · Soham · Wellingborough
NCT07503210 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC · started 2022-01-14
Aberdeen · Truro · London-Camden
NCT05139017 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen · started 2025-11-28
London · Sutton
NCT07213674 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple Myeloma
AbbVie · started 2025-07-23
Manchester
NCT06953960 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC · started 2025-05-13
Cambridge · London · Exeter · Birmingham · Northwood
NCT06925737 on ClinicalTrials.gov ↗
Starting soon Phase 3
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Scancell Ltd · started 2026-12-01
London
NCT07815574 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca · started 2025-03-01
Cambridge · Coventry · Dundee · London · Manchester
NCT06764875 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Contineum Therapeutics · started 2026-01-08
Leicester · London · Southampton · Edinburgh · Perth
NCT07284459 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-03-16
Truro · London · Nottingham · Taunton · Birmingham
NCT06841354 on ClinicalTrials.gov ↗
Active Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Prostate Cancer
Astellas Pharma Global Development, Inc. · started 2016-12-22
Bebington · Belfast · Bristol · Cambridge · Cardiff
NCT02960022 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi · started 2025-08-06
Cambridge · Dundee · London · Glasgow · Bath
NCT07088068 on ClinicalTrials.gov ↗
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices · started 2024-03-15
Brighton · London · Newcastle upon Tyne
NCT05932615 on ClinicalTrials.gov ↗
Recruiting Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca · started 2024-11-27
London · Manchester · Norwich · Nottingham · Plymouth
NCT06526793 on ClinicalTrials.gov ↗
Recruiting
Vercise™ DBS Dystonia Prospective Study
Dystonia
Boston Scientific Corporation · started 2016-03-07
Bristol · Glasgow · London · Newcastle upon Tyne
NCT02686125 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC · started 2025-04-11
Bristol · Aylesbury · Exeter · Plymouth · Middlesbrough
NCT06890884 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated · started 2026-05-13
Birmingham · London · Salford
NCT07501702 on ClinicalTrials.gov ↗
Active Phase 3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Large B-Cell Lymphoma
Hoffmann-La Roche · started 2023-09-18
Barnet · Blackpool · Canterbury · Exeter · Glasgow
NCT06047080 on ClinicalTrials.gov ↗
By invitation Phase 3
An Open-label Study of XEN1101 in Epilepsy
Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc. · started 2023-04-25
Leeds · Cardiff · Birmingham · London · Oxford
NCT05718817 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
Hoffmann-La Roche · started 2024-08-14
London
NCT05861999 on ClinicalTrials.gov ↗
Active Phase 2
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals · started 2022-12-06
Torquay
NCT05445843 on ClinicalTrials.gov ↗
Active Phase 2
A Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
Apogee Therapeutics, Inc. · started 2024-04-29
Salford · Dudley · London
NCT06395948 on ClinicalTrials.gov ↗
Active Phase 3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2020-12-08
Aberdeen · Dundee · Taunton · London · Manchester
NCT04624204 on ClinicalTrials.gov ↗
Active Phase 1/Phase 2
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Type 1 Diabetes
Vertex Pharmaceuticals Incorporated · started 2023-05-16
Headington · Newcastle upon Tyne
NCT05791201 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca · started 2025-04-21
Bristol
NCT06897930 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer · started 2024-08-28
Torquay · Belfast · Guildford · Cardiff
NCT06452277 on ClinicalTrials.gov ↗
Recruiting Phase 1
Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet
Healthy
Galmed Pharmaceuticals Ltd · started 2025-12-25
London
NCT07251712 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis · started 2025-07-21
Birmingham · Cardiff · Glasgow · Liverpool · London
NCT06943755 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Vector Y Therapeutics · started 2025-12-19
London · Sheffield
NCT07287397 on ClinicalTrials.gov ↗
Recruiting Phase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
ONL Therapeutics · started 2025-10-28
Gloucester · London · Newcastle · Southampton · Sunderland
NCT06659445 on ClinicalTrials.gov ↗
By invitation Phase 2/Phase 3
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Erythropoietic Protoporphyria
Disc Medicine, Inc · started 2023-08-31
London · Dundee · Salford
NCT05883748 on ClinicalTrials.gov ↗
Active Phase 3
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated · started 2022-11-08
Birmingham · Bristol · Cambridge · Edinburgh · Exeter
NCT05444257 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
AstraZeneca · started 2026-08-24
Airdrie · Chippenham · Hull · Llandough · Rotherham
NCT07776509 on ClinicalTrials.gov ↗
Active Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH · started 2025-06-30
Cambridge · Liverpool · London · Swindon · Truro
NCT06979531 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche · started 2018-03-30
Glasgow · London
NCT03424005 on ClinicalTrials.gov ↗
Recruiting Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca · started 2024-03-14
Birmingham · Bristol · Liverpool · London · Manchester
NCT05835310 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pridopidine Phase 3 Study in Huntington's Disease
Huntington Disease
Prilenia · started 2026-07-01
Aberdeen · Birmingham · Cardiff · Liverpool · Newcastle upon Tyne
NCT07609108 on ClinicalTrials.gov ↗
Recruiting Phase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc. · started 2025-08-28
Guildford · Cambridge · Cardiff · London · Southampton
NCT06960213 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc. · started 2026-02-17
Manchester
NCT07335497 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Non-Arteritic Anterior Ischemic Optic Neuropathy
Dompé Farmaceutici S.p.A · started 2026-07-01
London · Liverpool
NCT07453888 on ClinicalTrials.gov ↗
Recruiting Phase 2
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Rhinovirus Infection
Altesa Biosciences, Inc. · started 2026-05-01
Bromborough · Glasgow · London · Milton Keynes · Wolverhampton
NCT07610395 on ClinicalTrials.gov ↗
Recruiting Phase 2
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc. · started 2024-10-03
Cardiff · Plymouth · Wakefield
NCT05947955 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Neoplasms
Janssen Research & Development, LLC · started 2023-12-20
London · Oxford
NCT06150157 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
Hypercholesterolaemia
AstraZeneca · started 2026-08-12
Coventry · Knutsford · London · Orpington · Poole
NCT07619131 on ClinicalTrials.gov ↗
Recruiting
Safety and Effectiveness of Orbera365™ Intragastric Balloon System
Obesity
Boston Scientific Corporation · started 2026-04-07
Coventry
NCT07062094 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
Obesity, Overweight
Boehringer Ingelheim · started 2026-06-30
Blackpool · Guisborough · High Wycombe · Leicester · Middlesbrough
NCT07662122 on ClinicalTrials.gov ↗
Active Phase 3
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Systemic Sclerosis, Scleroderma
AstraZeneca · started 2023-11-08
Cannock · Leeds · London · Sheffield
NCT05925803 on ClinicalTrials.gov ↗
Active Phase 3
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Hormone-Sensitive Prostate Cancer
AstraZeneca · started 2020-07-13
Cambridge · Guildford · Manchester · Plymouth · Sutton
NCT04493853 on ClinicalTrials.gov ↗
Recruiting Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. · started 2023-08-10
London
NCT05997615 on ClinicalTrials.gov ↗
Recruiting Phase 1
First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency
Luteal Phase Insuffiency, Progesterone Delivery
Calla Lily Clinical Care Ltd · started 2026-04-20
Coventry
NCT07136922 on ClinicalTrials.gov ↗
Active
Versius Paediatrics Study
Robotic Surgical Procedures in Pediatric Urology
CMR Surgical Ltd · started 2024-07-08
London · Manchester · Southampton
NCT06539442 on ClinicalTrials.gov ↗
Active Phase 2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Ovarian Cancer
Hoffmann-La Roche · started 2021-10-07
Edinburgh · London
NCT04931342 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Bayer · started 2025-03-21
Manchester · Sutton
NCT06914128 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Chronic Hepatitis D
Mirum Pharmaceuticals, Inc. · started 2026-02-26
Cottingham · Cardiff · London · Manchester
NCT07454837 on ClinicalTrials.gov ↗
Recruiting Phase 2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Clostridioides Difficile Infection
AstraZeneca · started 2025-12-10
Birmingham · Cambridge · Cardiff · Newcastle
NCT07285213 on ClinicalTrials.gov ↗
Recruiting Phase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH · started 2025-03-18
Bristol · Glasgow · Salford · Southampton
NCT07032662 on ClinicalTrials.gov ↗
Active Phase 1
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Myeloid Diseases
Novartis Pharmaceuticals · started 2023-05-08
Cardiff · London · Manchester
NCT05552469 on ClinicalTrials.gov ↗
Recruiting Phase 1
Phase 1 Study of ADX-626 in Healthy Participants
Healthy Adult Participants
ADARx Pharmaceuticals, Inc. · started 2025-08-12
London
NCT07081503 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC · started 2018-08-21
Aberdeen · Cambridge · Edinburgh · Manchester · Sheffield
NCT03486873 on ClinicalTrials.gov ↗
Active Phase 2
A Study of Mosliciguat in PH-ILD
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc. · started 2024-10-29
Cambridge · London · Clydebank
NCT06635850 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Hoffmann-La Roche · started 2026-11-30
Chertsey
NCT07717411 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Obesity
Eli Lilly and Company · started 2025-11-24
Altrincham · Ashton-under-Lyne · Bolton · Bury · Cheshire
NCT07247084 on ClinicalTrials.gov ↗
Active Phase 3
Long-term Extension of GTX-102 in Angelman Syndrome
Angelman Syndrome
Ultragenyx Pharmaceutical Inc · started 2024-07-31
Cambridge · London · Oxford
NCT06415344 on ClinicalTrials.gov ↗
Active Phase 3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S · started 2023-02-13
Belfast · Cardiff · London · Sheffield
NCT05685238 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Healthy Participants, Obesity
AstraZeneca · started 2026-03-30
Harrow
NCT07511205 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Connective Tissue Diseases
GlaxoSmithKline · started 2024-12-12
Leeds · London
NCT06716606 on ClinicalTrials.gov ↗
Active Phase 3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Small-Cell Lung Cancer
Hoffmann-La Roche · started 2021-11-18
Blackpool · GB Manchester · Hull · Leeds · Leicester
NCT05091567 on ClinicalTrials.gov ↗
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical · started 2023-01-06
London · Newcastle upon Tyne · Oxford
NCT05701917 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Weight Management
AstraZeneca · started 2026-06-29
Ashton-under-Lyne · Blackpool · Chesterfield · Corby · Ely
NCT07667803 on ClinicalTrials.gov ↗
By invitation Phase 3
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Hypochondroplasia
BioMarin Pharmaceutical · started 2025-06-20
London
NCT07073014 on ClinicalTrials.gov ↗
Active Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Novo Nordisk A/S · started 2024-06-25
Truro · Torquay · Bournemouth · Ashford · Blackpool
NCT06118281 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
Refractory Chronic Cough and Unexplained Chronic Cough
Sensory Cloud, Inc. · started 2026-07-13
Belfast · London
NCT07690059 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca · started 2026-08-24
Ashton-under-Lyne · Basildon · Belfast · Birmingham · Brighton
NCT07761117 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Chronic Kidney Disease
AstraZeneca · started 2026-08-21
Aberdeen · Cardiff · Corby · Coventry · Dundee
NCT07753993 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc · started 2024-03-25
Chelsea · Oxford · Sutton
NCT06253871 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
Gilead Sciences · started 2022-12-12
Cottingham · Edgbaston · Liverpool · London · Manchester
NCT05633654 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Episodic Migraine
H. Lundbeck A/S · started 2023-06-08
Edinburgh · Great Yarmouth · Glasgow · London
NCT05897320 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
PS-002 for the Treatment of IgA Nephropathy in Adults
Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited · started 2026-03-30
Manchester · Leicester · Nottingham · Bristol · Cardiff
NCT07182227 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Hoffmann-La Roche · started 2025-05-05
Blackpool · Leicester · Shipley · Coventry · Northwood
NCT06965413 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
Stemline Therapeutics, Inc. · started 2022-08-31
Leicester · Liverpool · London · Manchester
NCT05386108 on ClinicalTrials.gov ↗
Recruiting Phase 3
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
X-linked Retinoschisis
Atsena Therapeutics Inc. · started 2023-08-22
Oxford
NCT05878860 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Colitis Ulcerative, Ulcerative Colitis
Merck Sharp & Dohme LLC · started 2026-03-24
Bury · Huddersfield
NCT07463183 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
AbbVie · started 2026-05-20
Cambridge
NCT07306832 on ClinicalTrials.gov ↗
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
ATTR Amyloidosis
AstraZeneca · started 2023-08-21
London
NCT06355934 on ClinicalTrials.gov ↗
Active Phase 2
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Hoffmann-La Roche · started 2023-11-29
London · Oxford
NCT06128564 on ClinicalTrials.gov ↗
Starting soon Phase 2
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Colorectal Adenocarcinoma
Vividion Therapeutics, Inc. · started 2026-09-15
London · Coventry
NCT07811193 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc. · started 2026-05-06
Aberdeen · Manchester
NCT07549412 on ClinicalTrials.gov ↗
Recruiting Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Crohn Disease, Colitis, Ulcerative
Merck Sharp & Dohme LLC · started 2024-11-25
London · Prescot
NCT06651281 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
RIG 101 Trial in Healthy Adults and Adults With Asthma
Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
RIGImmune Inc. · started 2026-02-09
London · Manchester
NCT07488897 on ClinicalTrials.gov ↗
Recruiting Phase 3
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Secondary Immune Deficiency
CSL Behring · started 2026-09-11
London · Leicester
NCT07648264 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals · started 2026-03-09
Bristol · London · Newcastle upon Tyne · Southampton
NCT07441642 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Episodic Migraine
AbbVie · started 2023-05-01
London · Gillingham · Aberdeen · Stockport
NCT05711394 on ClinicalTrials.gov ↗
Recruiting Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca · started 2026-02-03
Cambridge · Dundee · Leeds · London · Manchester
NCT07431281 on ClinicalTrials.gov ↗
Recruiting Phase 4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Swedish Orphan Biovitrum · started 2026-08-05
Cambridge · Cardiff · Glasgow · Leicester · London
NCT07746895 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-06-27
London · Manchester
NCT06998524 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA)
Hoffmann-La Roche · started 2022-06-02
Birmingham · Oxford
NCT05115110 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene · started 2022-09-20
Cambridge · Truro · Airdrie · London · Leicester
NCT05519085 on ClinicalTrials.gov ↗
Active Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc. · started 2023-10-18
Liverpool · Belfast · Birmingham · Cambridge · London
NCT05968326 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated · started 2022-03-30
Basildon · Bellshill · Birmingham · Carshalton · Leicester
NCT05312879 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 107 Manchester · 36 Cambridge · 30 Birmingham · 28 Glasgow · 26 Cardiff · 21 Leicester · 20 Leeds · 19 Oxford · 18 Bristol · 14 Edinburgh · 13 Sutton · 13 Liverpool · 13 Nottingham · 10 Newcastle upon Tyne · 10 Plymouth · 10

Browse by condition

Obesity · 6 Ovarian Cancer · 4 Non-small Cell Lung Cancer · 3 Ulcerative Colitis · 3 Marginal Zone Lymphoma · 2 Breast Neoplasms · 2 Triple Negative Breast Neoplasms · 2 Chronic Lymphocytic Leukemia · 2 Primary Membranous Nephropathy · 2 Dystonia · 2 Lymphoma, Large B-Cell, Diffuse · 2 Follicular Lymphoma (FL) · 2 Atopic Dermatitis · 2 Breast Cancer · 2 Diffuse Large B-Cell Lymphoma · 2 Metastatic Colorectal Cancer · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk (Accessed: 14 September 2026).

Embed this data ↗

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.